Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.

Yip SM, Laird AD, Agarwal N, Zschäbitz S, Fizazi K, Matsubara N, Joung JY, Karsh LI, Carles J, Fay AP, Piulats JM, Fong PCC, Liu G, Albacker LA, Pasquina LW, Chelliserry J, Healy CG, Lin X, Kalac M, Azad AA

Open source

DOI: 10.1016/s1470-2045(26)00355-4
Published: 2026 Oct 28
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00355-4,
  title = {Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.},
  author = {Yip SM and Laird AD and Agarwal N and Zschäbitz S and Fizazi K and Matsubara N and Joung JY and Karsh LI and Carles J and Fay AP and Piulats JM and Fong PCC and Liu G and Albacker LA and Pasquina LW and Chelliserry J and Healy CG and Lin X and Kalac M and Azad AA},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00355-4},
  url = {https://doi.org/10.1016/s1470-2045(26)00355-4}
}

RIS

TY  - JOUR
TI  - Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.
AU  - Yip SM
AU  - Laird AD
AU  - Agarwal N
AU  - Zschäbitz S
AU  - Fizazi K
AU  - Matsubara N
AU  - Joung JY
AU  - Karsh LI
AU  - Carles J
AU  - Fay AP
AU  - Piulats JM
AU  - Fong PCC
AU  - Liu G
AU  - Albacker LA
AU  - Pasquina LW
AU  - Chelliserry J
AU  - Healy CG
AU  - Lin X
AU  - Kalac M
AU  - Azad AA
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00355-4
UR  - https://doi.org/10.1016/s1470-2045(26)00355-4
ER  -

APA

SM, Y., AD, L., N, A., S, Z., K, F., N, M., JY, J., LI, K., J, C., AP, F., JM, P., PCC, F., G, L., LA, A., LW, P., J, C., CG, H., X, L., M, K., & AA, A. (2026). Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00355-4

Source records

pubmed · retrieved 2026-11-10T13:26:20.679Z